A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic Melanoma

Trial Profile

A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic Melanoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Ipilimumab (Primary) ; BCG vaccine; Isoniazid
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Apr 2017 Results presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 16 Jun 2016 Status changed from recruiting to discontinued due to slow recruitment as a result of changes in standard of care.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top